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Abstract: (1) Background: RNA viruses and especially coronaviruses could act inside host cells not 
only by building their own proteins, but also by perturbing the cell metabolism. We show the 
possibility of miRNA-like inhibitions by the SARS-CoV-2 concerning for example the hemoglobin 
and type I interferons syntheses, hence highly perturbing oxygen distribution in vital organs and 
immune response as described by clinicians; (2) Methods: We compare RNA subsequences of SARS-
CoV-2 protein S and RNA-dependent RNA polymerase genes to mRNA sequences of beta-globin 
and type I interferons; (3) Results: RNA subsequences longer than eight nucleotides from SARS-
CoV-2 genome could hybridize subsequences of the mRNA of beta-globin and of type I interferons; 
(4) Conclusions: Beyond viral protein production, Covid-19 might affect vital processes like host 
oxygen transport and immune response. 
Keywords: SARS-CoV-2; microRNA-like inhibition; oxygen metabolism; beta-globin translation 
inhibition; type I interferons translation inhibition. 
1. Introduction 
     Viruses act in host cells by reproducing their own proteins for reconstituting their capsid, 
duplicating their genome [1] and leaving non-coding RNA or DNA remnants in host genomes [2]. 
Moreover, RNA viruses can also form complexes with existing mRNAs and/or proteins of host cells. 
Thereby they might prevent protein function, behave like microRNAs [3-6] or ribosomal RNAs [6-8], 
inhibiting or favoring the translation of specific proteins of host cells [9-17]. If these proteins are vital 
for the host, viral pathogenicity is much greater than that caused by viral replication. With regard to 
SARS-CoV-2, binding to existing host proteins has already been described [18]. Here, we aim to 
describe a potential miRNA-like action by viral RNA, in particular i) at the level of oxygen transport 
by hemoglobin, whose beta-globin and gamma 2 subunits synthesis can be inhibited, and ii) at the 
level of immune response, where type I interferon synthesis can be inhibited. We are not intending 
to prove here experimentally these inhibitions by small RNAs issued from the SARS-CoV-2 genome, 
but to prepare this future empirical step by pointing out its potential hybridizing power. In Section 
2, we describe a method for finding SARS-CoV-2 inhibitory RNA sub-sequences, and results are 
given in Section 3, we discussed in Section 4. Some perspectives of this work concerning an extension 
to the inhibition of translation of olfactory and interferon receptors are proposed in Section 5. 
2. Methods 
     Focusing on the seed part of miRNA-like sequences having a putative 8 nucleotide 
hybridization seed inhibition effect [19-20] (minimum 7), we compare data from different databases 
  
[21-26] using BLAST [27]. Figure 1 shows microRNA 129-5p, a known inhibitor of a human foetal 
hemoglobin component, the gamma-globin 2, replaced in adult by the beta-globin regulated as the 
other component alpha-globin, by microRNAS [28-32]. Two sub-sequences from the SARS-CoV-2 
genome, namely from genes of ORF10 and protein S, show the same hybridizing potential. 
Homo sapiens hemoglobin subunit gamma 2 (HBG2), mRNA NCBI Reference Sequence: NM_000184.3 








          protein S gene SARS-CoV-2 3’-CTGAAGTAGTGGAGATTAATGT-5’ 
CCACTGAGCTCACTGCCCATGATGCAGAGCTTTCAAGGATAGGCTTTATTCTGCAAGCAATCAAATAATA 
               ORF10 gene SARS-CoV-2 3’-TTCTAAGTAAGACGTGTTCTCATCTG-5’      
           AATCTATTCTGCTAAGAGATCACACA-3’ 
Figure 1. Complete mRNA sequence of the subunit gamma 2 of the fetal human hemoglobin [22]. 
Sequences in green (resp. red) come from protein S and ORF10 genes of SARS-CoV-2 (resp. hsa miR 129-
5p), which can inhibit its ribosomal translation. Probability of length 8 anti-match in red (resp. 9 and 11 
in green) by chance in 577 nucleotides equals 0.035 (resp. 0.017 and 0.0003) (T-G and G-T matches 
counting for ½).  
3. Results 
     We will apply the method from Section 2 for showing examples where RNA subsequences of 
the SARS-CoV-2 genome have an inhibitory potential on the ribosomal translation of human mRNAs 
of the same type as that shown in Section 2 for human micro-RNAs. For example, miRTarBase shows 
that microRNA hsa-mir-92a-3p targets the beta-globin HBB subunit of adult hemoglobin, inhibiting 
its translation [25]. This is also the case for microRNas involved in the maturation of erythrocytes like 
miR-451a [26-31]. We exhibit on Figure 2 subsequences of the SARS-CoV-2 protein S and polymerase 
genes [23] having the same length of antimatching as these microRNAs on the mRNA of the 
hemoglobin beta-globin (HBB) subunit gene.  
 
Homo sapiens hemoglobin subunit beta (HBB), mRNA NCBI Reference Sequence: NM_000518.5 
        5’-ACATTTGCTTCTGACACAACTGTGTTCACTAGCAACCTCAAACAGACACCATGGTGCATCTGACTCCTGAGGA 
               RNA-dependent RNA polymerase SARS-CoV-2   3’-TCACGTAGAACTAGGAGTATT-5’ 
           GAAGTCTGCCGTTACTGCCCTGTGGGGCAAGGTGAACGTGGATGAAGTTGGTGGTGAGGCCCTGGGCAGGCTG 
           CTGGTGGTCTACCCTTGGACCCAGAGGTTCTTTGAGTCCTTTGGGGATCTGTCCACTCCTGATGCTGTTATGG  
           GGCAACCCTAAGGTGAAGGCTCATGGCAAGAAAGTGCTCGGTGCCTTTAGTGATGGCCTGGCTCACCTGGACA 
                               mir-451a   3’-TTGAGTCATTACCATTGCCAAA-5’ 
           CCTCAAGGGCACCTTTGCCACACTGAGTGAGCTGCACTGTGACAAGCTGCACGTGGATCCTGAGAACTTCAGG 
                                                                         3’-TGTCCGGC 
           CTCCTGGGCAACGTGCTGGTCTGTGTGCTGGCCCATCACTTTGGCAAAGAATTCACCCCACCAGTGCAGGCTG  
           CCTGTTCACGTTAT-5’ miR-92a-3p    
           CCTATCAGAAAGTGGTGGCTGGTGTGGCTAATGCCCTGGCCCACAAGTATCACTAAGCTCGCTTTCTTGCTGT 
              3’-ATTTTCACCTTTTACTACGCC-5’ Protein S SARS-CoV-2  
           CCAATTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCAACTACTAAACTGGGGGATATTATGAAGGGCCTTGA 
           GCATCTGGATTCTGCCTAATAAAAAACATTTATTTTCATTGCAA-3’ 
Figure 2. Human beta-globin gene [24] potentially targeted by a subsequence of the gene of the SARS-
CoV-2 RNA-dependent RNA polymerase (in blue) and by a subsequence of the gene of the SARS-
CoV-2 protein S (in green) [23], by the human microRNAs hsa miR 92a-3p (in red) and hsa miR 451a 
(in red). Probability of red anti-matches of length 8 in a sequence of 624 nucleotides equals 0.04 and 
for the blue (resp. green) subsequence is 0.005 (resp. 0.017) (T-G and G-T matches counting for ½).   
  
The second example concerns the gene of the spicule protein S of SARS-CoV-2, which shares a 
long subsequence of length 14 (664-678) with the gene of the Gag protein of the virus HERV-
K102 (Figure 3). Its potential targets are the mRNAs of human hemoglobin subunit beta-globin 
[22], human hemoglobin subunit gamma-globin 2 (HBG2) [23], human type 1 interferons and 
the human receptor ACE2.  
 
SARS coronavirus 2 isolate USA/MN1-MDH1/2020, complete genome GenBank: MT188341.1: 21512-25333 protein S 






















































           TCTGAGCCAGTGCTCAAAGGAGTCAAATTACATTACACATAA-3’ 
  
Figure 3. mRNA sequence of the protein S of the virus SARS-CoV-2 [23]. The first green subsequence 
of length 14 (664-678) occurs in mRNA of Gag protein of the virus HERV-K102 [27]. The second of 
length 23 (1112-1134) anti-matches a mRNA subsequence of hemoglobin subunit beta-globin [22]. 
The third of length 22 (1200-1221) anti-matches a mRNA subsequence of hemoglobin subunit 
gamma-globin 2 (HBG2) [23]. The fourth of length 24 (2032-2055) matches a subsequence of mRNA 
of many type 1 interferons. Highlighted in yellow are sub-sequences common with the SARS furin 
cleavage site [33-34]. The fifth of length 25 (3152-3176) matches a subsequence of mRNA of the 
receptor ACE2. Blue: mutations whose location of both codon and nucleotide involved [35] are, in 
order: 635 gCtagTt, 1133 aAgaaGg, 2045 cGgacAg and 3189 ttG>ttT. The probabilities of the above 
matches and anti-matches will be given in the following in Figures concerning each of them. 
 
Homo sapiens ACE2 mRNA, complete cds GenBank: AB046569.1    
   5’-TTTTTAGTCTAGGGAAAGTCATTCAGTGGATGTGATCTTGGCTCACAGGGGACGATGTCAAGCTCTTCCT 
GGCTCCTTCTCAGCCTTGTTGCTGTAACTGCTGCTCAGTCCACCATTGAGGAACAGGCCAAGACATTTTT 
GGACAAGTTTAACCACGAAGCCGAAGACCTGTTCTATCAAAGTTCACTTGCTTCTTGGAATTATAACACC 
           protein S SARS-CoV-2        3’-CTGTTTACCGTCCTCGTCAACACTT-5’ 































GTGGAGAAAATCCTTATGCCTCCATCGATATTAGCAAAGGAGAAAATAATCCAGGATTCCAAAACACTGA                      
TGATGTTCAGACCTCCTTTTAGAAAAATCTATGTTTTTCCTCTTGAGGTGATTTTGTTGTATGTAAATGT 
   TAATTTCATGGTATAGAAAATATAAGATGATAAAAATATCATTAAATGTCAAAACTATGACTCTGTTCAG-3’ 
Figure 4. mRNA sequence of the human protein receptor ACE2. The green 5’-3’ seed subsequence of 
length 10 is the reverse of an RNA sequence of the protein S of SARS-CoV-2. The probability to 
observe such an anti-match of length 10 by chance in a sequence of 2581 nucleotides equals 0.003. 
 
The classical protein-protein interaction of the spicule protein S of SARS-CoV-2 is with the human 
protein receptor ACE2, but there exists a putative miRNA-like translation inhibition due to a 
  
subsequence (in green) of the protein S gene (Figure 3) matching the ACE2 mRNA (Figure 4). The 
human endogenous retrovirus HERV-K102 [32] has been described as having an antagonizing power 
on HIV-1 replication, by stimulating antibody production. It is indeed capable of high replication rate 
in vivo and in vitro and this high particle production can stimulate an early protective innate immune 
response against HIV-1 replication. It could play the same role in SARS-CoV-2. A possible mechanism 
of this immune stimulation could be due to the fact that both Gag protein of HERV-K107 and protein 
S of SARS-CoV-2 share common sub-sequences as the subsequence of length 15 nucleotides from the 




Homo sapiens endogenous retrovirus HERV-K102, complete sequence GenBank: AF164610.1: 1112-2596 Gag protein 





















      CCATTAAGCCATTAA-3’ 
Figure 5. Complete RNA sequence of the Gag protein of the virus HERV-K102 [36]. The green 
subsequence of length 14 (271-285) is present in the RNA sequence of the protein S of virus SARS-
CoV-2 [22]. The probability to observe this match of length 14 by chance in a sequence of 1475 




     When we combine the antibody power originated by the endogenous human retrovirus HERV-
K102 envelop protein (whose part of its mRNA is shared by the SARS-CoV-2 protein S [36]) with the 
putative inhibitory role of circRNAs capable to block the miRNA-like action of SARS-CoV-2, one 
could understand why certain carriers of SARS-CoV-2 are completely asymptomatic and therefore, 
by mimicking their defence mechanisms, consider a possible therapy against SARS-CoV-2. Indeed, if 
we look on the “sponge effect” of circRNAs against microRNAs [37-39], one can consider a 
therapeutic effect erasing pathogenic actions of microRNAs.  
 
For example, in the case of the human let-7e microRNA, a sub-sequence of human circular RNA PVT1 
hybridizes hsa-let-7e (Figure 6), thus preventing it from exerting a too important inhibition on the 
translation of proteins such as the gamma-globin 2. There exists a sub-sequence of the protein S of 
SARS-CoV-2 (Figure 6), on which a similar action would be possible, hence reducing the miR-like 
  
pathogenicity of the protein S, but with less efficiency, with a hybridization free energy ΔG equal to 
-4.6 kcal/mol vs -11 for the hsa-let-7e. 
 
Homo sapiens Pvt1 oncogene (PVT1), long non-coding RNA NCBI Reference Sequence: NR_003367.3               





                                         hsa-let-7e 3’-CCTTTCGATCCTCCG 
ATGCACTGGAATGACACACGCCCGGCACATTTCAGGATACTAAAAGTGGTTTTAAGGGAGGCTGTGGCTG 






      GATTTGGAGAGAGTCTCACTCTGTGGTCCAGGCTGAAGTACAGTGGCATGATCCCAGGTCACTGCAACCC 
                   3’-GTGAGGTATGTGAATTTTCACC-5’ Protein S SARS-CoV-2 
   CCACCTCCCGGGTTCAAGTGATCCTCCTGCCTCAGCCTCCCGAGTAGCTGGTATTACAGGCGTGTGCCAC-3’ 
Figure 6. RNA sub-sequence of the circPVT1 [22]. The RNA sequence in red is the microRNAs hsa miR 
let-7 inhibited by its “sponge” hsa-circ-PVT1. The RNA sequence in green is a sub-sequence of the 
protein S of SARS-CoV-2 on which hsa-circ-PVT1 could serve as inhibitor. Anti-match probability of a 
sub-sequence of length 9 in a sequence of length 1946 is 0.06 (resp. 0.03) for the red (resp. green) sub-
sequence.   
We can also compare the putative miRNA-like inhibitory efficacy of the protein S in other 
coronaviruses than SARS-CoV-2. By taking for example the SARS CoV Rs672 virus observed in 2006, 
it is possible to exhibit in the RNA sequence of its protein S gene some sub-sequences similar to those 
from SARS-CoV-2 involved in a miRNA inhibitory effect (Figure 7): they have less nucleotides anti-
matching their protein targets, which could explain lesser virulence of the SARS epidemic than of the 
SARS-CoV-2 outbreak.  
Bat SARS CoV Rs672/2006, complete genome GenBank: FJ588686.1: 20894-24619 protein S 













   GTGTAGGTCAGAAATCCATTGTGGCTTACACTATGTCTTTGGGTGCAGAAAATTCTATTGCTTATGCTAA-3’ 
Figure 7. RNA sub-sequence of the SARS CoV Rs672 protein S gene. Nucleotides in green are 
homologous to those of SARS-CoV-2 protein S gene (in green on Figure 3), which could explain the 
lesser virulence of SARS as compared to SARS-CoV-2 due to fewer anti-matches with their miRNA-
like targets. The probability to observe by chance a sub-sequence of length 31 in a sequence of 3722 
nucleotides with exactly 3 errors equals 3 C331 0.2531 = 3 10-15 and for a sub-sequence of length 11 
equals 9 10-4. 
 
  
Among the symptoms of the Covid-19 disease, anosmia is frequently described. This defect could be 
due to a miRNA-like inhibition of mRNAs of genes from olfactory receptor family (Figure 8).  
Homo sapiens olfactory receptor family 4 subfamily E member 1 (OR4E1), mRNA NCBI Reference Sequence: NM_001317107.1 












                                                         3’-ATCGATGTGA 
GTTCCTGGGACACTGCATCTTCATCTATTCCCGCCCATCCACCAGCCTCCCAGAGGACAAGGTAGTATCT 




Figure 8. Complete mRNA sequence of the human olfactory receptor family 4 subfamily E member 1 
(OR4E1) [22]. The RNA sequence in green is a sub-sequence of the protein S of SARS-CoV-2, which can 
exert a miRNA-like inhibition of the translation of OR4E1. The probability to observe such an anti-
match of length 12 by chance in a sequence of 577 nucleotides equals 5 10-4.  
 
5. Perspectives 
     The perspectives of the present work are in the more in-depth study of unconventional 
mechanisms of action of the SARS-CoV-2 virus, in particular those concerning the disturbances of 
oxygen transport observed in many patients [41,42]. We can also notice the resemblance of a SARS-
CoV-2 sub-sequence with hsa-miR-let-7b, the microRNA the most upregulated in Kawasaki disease 
[43] described as potentially linked to SARS-CoV-2 infection [44]. The SARS-CoV-2 virus could have, 
more than a direct protein-protein interaction (proposed in [16] despite the criticisms of [45]), an 
effective inhibitory action in vivo of the same type as that predicted here in silico on the synthesis of 
subunits of human hemoglobin, and this action is more important for SARS-CoV-2 than for other 
coronaviruses (like the SARS CoV Rs672 on Figure 8). This hypothesis is in agreement with numerous 
studies showing a decrease of adult human hemoglobin blood concentrations in severe Covid-19 
cases [46,47], presenting an increase of the high-sensitivity C-reactive protein as one of the three major 
predictors of severity [48], like in ß-thalassemia [49] and viral infections [50]. Hence, one could 
envisage a therapy blocking pathologic inhibitor effects on ribosomal translation of hemoglobin 
subunits, using for example circular RNAs as blockers of possible viral miRNA-like mechanisms 
(Figure 7) [51-54]. Another direction could be to search if furin cleavage site sub-sequence has the same 
type of interaction with key proteins like Rac small GTPase (a protein from the Rho GTPase family, 
which is a strong determinant of the virus-induced IFNbeta response [55-56]), implicated in 
replication of many important viral pathogens infecting humans or like interferons. A first example 
is given by the human small GTPase 1 (Figure 9) in which the inhibition of the SARS-CoV-2 protein 
S gene is possibly obtained through the same miRNA-like subsequence as for all type 1 interferons. 
The host immune system is indeed reacting to viral intrusion first with synthesis of type I interferons 
IFNalphas and IFNbetas [57-58]. They are messengers allowing the activation of cellular defenses 
blocking viral replication. In humans, these type I interferons are bound to interferon receptors, and 
then, they induce proteins with antiviral actions: RNA-dependent protein kinase (PKR), 2′,5′-
oligoadenylate synthetase (OAS), RNase L, and Mx protein GTPases [59]. 
  
Homo sapiens Rac family small GTPase 1 (RAC1), transcript variant Rac1, mRNA NCBI Reference Sequence: NM_006908.5 





                                    protein S SARS-CoV-2      3’-GATGT 
CTGCATTGTTGTGCCGAGAACACCGAGCACTGAACTTTGCAAAGACCTTCGTCTTTGAGAAGACGGTAGC 






                                 protein S SARS-CoV-2      3’-GATGTGAT 
CATTGTACAAGGAATGAAAGTGTCACGGGTAAAAACTCTAAAAGGTTAATTTCTGTCAAATGCAGTAGAT 
              GATGCACG-5’ 
GATGAAAGAAAGGTTGGTATTATCAGGAAATGTTTTCTTAAGCTTTTCCTTTCTCTTACACCTGCCATGC 
CTCCCCAAATTGGGCATTTAATTCATCTTTAAACTGGTTGTTCTGTTAGTCGCTAACTTAGTAAGTGCTT 
   TTCTTATAGAACCCCTTCTGACTGAGCAATATGCCTCCTTGTATTATAAAATCTTTCTGATAATGCATTA-3’ 
Figure 9. MiRNA-like subsequence of SARS-CoV-2 protein S gene (from its furin cleavage site) anti-
matching a subsequence of the human GTPase 1 gene. The probability to observe such anti-matches of 
length 9 by chance in the of the 2301-length sequence of the whole human GTPase 1 gene equals 0.017. 
 
Homo sapiens interferon alpha 7 (IFNA7), mRNA NCBI Reference Sequence: NM_021057.2 







                                    hsa miR let-7b-5p 3’-CTTTGGTGTGTTG 
              ACTCTTTATCTAATGGAGAAGAAATACAGCCCTTGTGCCTGGGAGGTTGTCAGAGCAGAAATCATGAGAT 
              GATGATGGAG-5’                3’-TGCACGGGCGGCTCCTCTTAATC-5’ protein S SARS-CoV-2 
CCTTCTCTTTTTCAACAAACTTGAAAAAAGGATTAAGGAGGAAGGATTGAAAACTGGTTCATCATGGAAA 
TGATTCTCATTGACTAATGCATCATCTCACACTTTCATGAGTTCTTCCATTTCAAAGACTCACTTCTATA 
              ACCACCACAAGTTGAATCAAAATTTCCAAATGTTTTCCT-3’ 
 
Homo sapiens interferon regulatory factor 1 (IRF1), transcript variant 5, non-coding RNA NCBI RefSeq: NR_149069.2 
           5’-AGAGCTCGCCACTCCTTAGTCGAGGCAAGACGTGCGCCCGAGCCCCGCCGAACCGAGGCCACCCGGAGCC 
GTGCCCAGTCCACGCCGGCCGTGCCCGGCGGCCTTAAGAACCCGGCAACCTCTGCCTTCTTCCCTCTTCC 










GGCTTAGCAGAGGACAAACGAGTTAATCTTGCACCAGTCACTCTGGCCCAAGAAGCCTATAGCTGGTGCA   
CTTGGGGCAACATAGACCCTATAGACTTAGTAGCAATGATAGTATTCATAATAATAGCTAATGCTTACTG 
AACACTCCCTGTGTGCCTGGCACCTGCTAAGTATGTTATTTACATTGTGTCATTTAATCCTCGCAGTAGT 
                  3’-TGATGCACGGGCGGCTCCTCTT-5’ protein S SARS-CoV-2     
CCTGTGGGTTAGATCTTACTAATGTCATCATTTTCAGATAAGTAAACAGAGGCACTGAGAGGTAGATCAT 
              AAGATCACACAAAAAGTGATGAAGCCAAGATTTGAACTTGAACGGTCTGACTCAGAAATCTT-3’ 
  
Figure 10. MiRNA-like subsequence of SARS-CoV-2 protein S gene (from its furin cleavage site) anti-
matching sequences from the human type 1 interferon (IFNA7) or interferon regulatory factor (IRF1). 
In the first case, the sequence is the whole mRNA of IFNA7 and the probability to observe such an 
anti-match of length 8 by chance in a sequence of 730 nucleotides equals 0.04. In the second case, the 
sequence of the whole mRNA of IRF1 contains to targets and the probability to observe the last anti-
match of length 11 by chance in a sequence of 1032 nucleotides equals 2 10-3. In red, miRNA inhibiting 
sequences [59-60]. The probability to observe by chance the micro-RNA hsa miR let-7b-5p anti-match 
of length 9 in the first 730-length sequence equals 0.02 and the micro-RNA hsa miR 301a-3p anti-match 
of length 9 in the second 1032-length sequence equals 0.016. 
 
In the same way, the miRNA-like subsequence of SARS-CoV-2 protein S gene from its furin cleavage 
site) anti-matches the mRNA of the MCT1 gene involved in the lactate shuttle between astrocytes and 
neurons (Figure 11) and this effect decreases the energy provided to the brain [61]. That could explain 
some neurological and neuropsychiatric complications observed in SARS-COV-2 patients, since the 
earliest cohorts featured non-specific neurological symptoms, such as dizziness and headache. 
 
Homo sapiens clone peg2135 MCT1 (MCT1) mRNA, complete cds GenBank: AY364258.1 
           5’-ATGTTCAAGAAATTTGATGAAAAAGAAAATGTGTCCAACTGCATCCAGTTGAAAACTTCAGTTATTAAGG 
GTATTAAGAATCAATTGATAGAGCAATTTCCAGGTATTGAACCATGGCTTAATCAAATCATGCCTAAGAA 








      protein S SARS-CoV-2 3’-TGCACGGGCGGCTCCTCTT-5’  
              GCCTGTGGTTATGCT G-3’ 
Figure 11. MiRNA-like subsequence of SARS-CoV-2 protein S gene (from its furin cleavage site) anti-
matching the mRNA of the human MCT1 gene. The probability to observe this anti-match of length 9 
by chance in a sequence of 638 nucleotides equals 2.5 10-3. In red, the micro-RNA hsa miR 342-5p 
inhibiting the human MCT1 gene sequence with a subsequence of length 8 and this anti-match has the 
probability 0.02 to occur by chance in a sequence of 638 nucleotides.     
 
Eventually, the mutations observed on SARS-CoV-2 [35, 63-64] can be neutral (without any effect), 
favorable (less pathogenic) or deleterious (more pathogenic). Among them, we have (mutations in 
red): 
 
Neutral: Homo sapiens hemoglobin subunit gamma 2 (HBG2)       5’-GCTTTATTCTGCAAGCAA-3’ 
                                  protein S SARS-CoV-2       3’-TGAGGTATTGTGGATTTT-5’ 
           Homo sapiens Rac family small GTPase 1 (RAC1)         5’-CTGTGTGCCTGGCAC -3’ 
                                   protein S SARS-CoV-2          3’-GATGCACGGGCGACT-5’  
Favorable:                   Homo sapiens ACE2 mRNA  5’-GACAAATGGTCTGCCTTTTTAAAGG-3’ 
                                  protein S SARS-CoV-2  3’-CTTTTTACCGTCCTCGTCAACACTT-5’ 
          Homo sapiens interferon regulatory factor 1 (IRF1) 5’-CCTGTGTGCCTGGCACCTGCTA -3’                                  
                                   protein S SARS-CoV-2  3’-TGATGCACGGGCGACTCCTCTT -5’  
Deleterious:         Homo sapiens HERV-K102 Gag protein         5’-GCTTTAGAACCATTT-3’ 
                                   protein S SARS-CoV-2         5’-GTTTTAGAACCATTT-3’ 
               Homo sapiens hemoglobin betaglobin (HBB)  5’-TCAGAAAGTGGTGGCTGGTGTGG-3’ 
                               protein S SARS-CoV-2   3’-GGATTTTCACCTTTTACTACGCC-5’ 
 
  
We can notice also that the protein S gene is not the only SARS-CoV-2 gene anti-matching important 


























   
 
 
     DNA at 37°C, CT = 0.00001 M            
       [Na+] = 1 M, [Mg++] = 0 M 
ΔG = -9.0 kcal/mol, ΔH = -85.9 kcal/mol 
         DNA at 37°C, CT = 0.00001 M 
        [Na+] = 1 M, [Mg++] = 0 M 
          ΔG = -8.8 kcal/mol, ΔH = -66.3 kcal/mol 
Figure 12. Hybridization between subsequences from SARS-CoV-2 genome and human genome. Left: 
hybridization between a subsequence of the SARS-CoV-2 Protein S gene and a subsequence of the gene of 
the human hemoglobin beta-globin (HBG) subunit (Figure 2). Right: hybridization between a subsequence 
of the SARS-CoV-2 ORF10 gene and a subsequence of the gene of the human hemoglobin gamma-globin 
2 (HGG 2) subunit (Figure 1).  
 
On Figure 12, the free energy and enthalpy are given in kcal/mol for two hybridizations [65-66] 
between subsequences of SARS-CoV-2 genes and subsequences of genes of two important proteins 
of the human metabolism of oxygen, involved in the oxygen transportation in adult for the first (the 
human hemoglobin beta-globin (HBG) subunit) and the in embryo for the second (the human 
hemoglobin gamma-globin 2 (HGG 2) subunit). 
 
We have summarized the probabilities of anti-matches of Figures 2 to 11 and in Table 1, allowing for 
the comparison between the classical miRNA action and the putative inhibitory influence the protein 




Table 1. Probability P and free energy ΔG (kcal/mol) of anti-matching between human genes and protein S gene subsequence 
(TG and GT counting for ½). 
Matching subsequence  Human/viral gene P ΔG Fig.  
protein S CTTCATTTTCAACTTTTAAATGTTATGGAGT virus SARS CoV Rs672 Protein S 3 10-15  7 
protein S GCTTTAGAACCATT HERV-K102 protein Gag 10-6  5 
Anti-matching subsequence      
hsa-miR-129-5p TGTCGTTC human g-globin 2 0.035 -6.7 1 
protein S CTGAAGTAG human g-globin 2 0.017 -2.6 1 
ORF10 AAGTAAGACGT human g-globin 2 3 10-4 -8.8 1 
RNA-dependent RNA polymerase ORF1ab 
TCACGTAGAACTAGGAGTATT 
human beta-globin 5 10-3 -11.2 2 
miR 451a TGAGTCAT human beta-globin 0.04 -3.2  2 
protein S TTTTCACC human beta-globin 0.017 -9  2 
miR 92a-1-5p TGTCCGGC human beta-globin 0.04 -8.2  2 
protein S CTGTTTACCG human ACE2 3 10-3 -9.5  4 
protein S GTGAGGTAT human circPVT1 0.03 -4.6  6 
let-7e CCTTTCGAT human circPVT1 0.06 -11  6 
               protein S ATCGATGTGATG human olfactory receptor OR4E1 5 10-4 -7.7  8 
protein S GATGTGATG human GTPase 1 0.017 -6.8  9 
let-7b-5p CTTTGGTGT human type 1 interferon IFNA7 0.04 -3.2  10 
protein S GCACGGGC human type 1 interferon IFNA7 0.04 -10.7  10 
miR 301a-3p GTCTACGAA  human type 1 interferon IRF1 0.016 -3.6  10 
protein S GATGCACGGGC human interferon regulatory factor 
IRF1 
2 10-3 -8  10 
miR 342-5p GAGTTAGT human MCT1 0.02 -3.9  11 




To conclude, the natural history of the SARS-CoV-2 virus remains widely unknown and it is still too 
early to say whether the many mutations observed will cause it to evolve in a favorable direction 
from a human point of view. There are for example some mutations surely deleterious [66,67], but 
also others favoring the positive role of some human miRNAs against SARS-CoV-2 [68-70] suggesting 
a possible therapy. The present proposal of a miRNA-like mechanism would at least allow to see, for 
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